Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

Onyema Ogbuagu, Sorana Segal‐Maurer, Sorana Segal-Maurer, Winai Ratanasuwan, Cynthia Brinson, Cynthia Brinson, Andrea Antinori, Yazdan Yazdanpanah, Benoît Trottier, Hui Wang, Nicolas Margot, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Jean‐Michel Molina, Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Peter Ruane, Gary Ian Sinclair, Kenneth Lichtenstein, Moti Ramgopal, Andrew Wiznia, Andrew Wiznia, William E. Sanchez, Cynthia Brinson, Joseph P. McGowan, Catherine Creticos, Daniel S Berger, David A. Wheeler, Debbie Hagins, Gordon Crofoot, James J. Sims, Olayemi Osiyemi, Theo Hodge, Christine Zurawski, Onyema Ogbuagu, Sorana Segal‐Maurer, Onyema Ogbuagu, Sorana Segal-Maurer, Krittaecho Siripassorn, Ploenchan Chetchotisakd, Antonella Castagna, Andrea Antinori, Francesco Castelli, Sylvie Ronot-Bregigeon, Jean‐Michel Molina, Yazdan Yazdanpanah, Benoît Trottier, Jason Brunetta, Takuma Shirasaka, Yoshiyuki Yokomaku, Ellen Koenig, Josep Mallolas, Hans‐Jürgen Stellbrink, Chien‐Ching Hung, Mohammed Rassool, Chien‐Ching Hung, Mohammed Rassool